Treatment for Reactive Airway Disease
Treat reactive airway disease using the same stepwise approach as asthma, starting with inhaled short-acting beta agonists as needed for intermittent symptoms, and advancing to low-dose inhaled corticosteroids for persistent symptoms. 1
Understanding the Terminology
The term "reactive airway disease" (RAD) is problematic and non-specific. It encompasses two distinct clinical entities:
- Reactive Airways Dysfunction Syndrome (RADS): A true occupational asthma variant caused by sudden, high-level exposure to irritant gases, vapors, or fumes in previously healthy individuals 2, 3
- RAD as a diagnostic label: Often used interchangeably with asthma in young children, though this practice delays appropriate preventive care 4
Treatment Algorithm
Step 1: Intermittent Symptoms
- Preferred: Inhaled short-acting beta agonist (SABA) as needed 1
- Add patient education, environmental control, and management of comorbidities at every step
Step 2: Mild Persistent Disease
- Preferred: Low-dose inhaled corticosteroid 1
- Alternatives: Leukotriene receptor antagonist (montelukast or zafirlukast), cromolyn, nedocromil, or theophylline 1
- Montelukast offers advantages of once-daily dosing and high compliance rates, with fewer respiratory infections in some studies 1
Step 3: Moderate Persistent Disease
- Preferred: Low-dose inhaled corticosteroid PLUS long-acting beta agonist, OR medium-dose inhaled corticosteroid alone 1
- Alternatives: Low-dose inhaled corticosteroid plus leukotriene receptor antagonist, theophylline, or zileuton 1
Step 4 and Beyond
- Escalate to medium- or high-dose inhaled corticosteroids combined with long-acting beta agonists 5
- Consider omalizumab for allergic patients at Steps 5-6 1
- Add oral corticosteroids only at Step 6 for severe, refractory disease 5
Critical Decision Points
When to step up treatment: If SABA is needed more than 2 days per week for symptom relief (excluding exercise-induced bronchospasm prevention), this indicates inadequate control 1
Before stepping up: Always verify medication adherence, environmental control measures, and address comorbid conditions 5
When to step down: After at least 3 months of well-controlled asthma 1
Special Considerations for RADS
For true Reactive Airways Dysfunction Syndrome following acute irritant exposure:
- Most patients recover completely without long-term sequelae if they survive the initial exposure 2
- Standard asthma treatment applies, though some severe cases may be refractory to conventional bronchodilators and corticosteroids 6
- For refractory cases, case reports suggest potential benefit from nebulized lidocaine 6 or high-dose vitamin D 7, though these remain experimental approaches
Common Pitfalls to Avoid
Don't use "RAD" as a diagnosis in children: This label delays delivery of asthma action plans and controller medications by an average of 9 months 4. Make a clear asthma diagnosis when appropriate to ensure timely preventive care.
Don't assume low-level chronic exposures cause RADS: The evidence for "low-level RADS" is controversial and likely represents preexisting asthma or atopic predisposition rather than true RADS 2
Don't forget theophylline monitoring: If using theophylline, serum concentration monitoring is mandatory 1
Don't use zileuton as first-line: It requires liver function monitoring and has limited evidence as adjunctive therapy 1, 5
Monitoring Treatment Response
Use validated questionnaires (Asthma Control Test, Asthma Control Questionnaire) or spirometry to assess control 5. Target FEV₁ or peak flow ≥80% of predicted for well-controlled disease, with values <60% indicating very poor control requiring immediate treatment escalation 5.